fulvestrant

Poland

Drugs containing this active substance

  • FULVESTRANT ACCORD

    The medicine is used to treat postmenopausal women with a certain type of breast cancer (locally advanced or metastatic) that is hormone receptor-positive. It may also be used in combination with palbociclib in women with hormone receptor-positive breast cancer (without HER2 overexpression).

    Form: solution for injection in ampoule-syringe

    Active substance Dosage
    fulvestrant 250 mg/5 ml

    ATC: L02BA03

    Manufacturer: Accord Healthcare Polska Sp. z o.o. Pharmadox Healthcare Ltd.

  • FULVESTRANT CIPLA

    The medicine is used in postmenopausal women for the treatment of a certain type of breast cancer (locally advanced or metastatic) that has estrogen receptors. It may also be used in combination with another medicine (palbociclib) in women with a similar type of cancer, and in premenopausal women – in combination with an additional medicine.

    Form: solution for injection in ampoule-syringe

    Active substance Dosage
    fulvestrant 250 mg/5 ml

    ATC: L02BA03

    Manufacturer: Laboratorios Farmalán, S.A.

  • FULVESTRANT EUGIA

    This medicine is used to treat postmenopausal women with locally advanced or metastatic breast cancer that is hormone receptor-positive. It may also be used in combination with palbociclib in women with hormone receptor-positive breast cancer (without HER2 overexpression).

    Form: solution for injection in ampoule-syringe

    Active substance Dosage
    fulvestrant 250 mg/5 ml

    ATC: L02BA03

    Manufacturer: APL Swift Services (Malta) Ltd. Arrow Generiques Generis Farmacêutica, S.A.

  • FULVESTRANT EVER PHARMA

    The medicine is used in the treatment of postmenopausal women with a certain type of breast cancer (estrogen receptor-positive) that is locally advanced or has metastasized. It may also be used in combination with palbociclib in women with hormone receptor-positive breast cancer (without overexpression of the HER2 receptor).

    Form: solution for injection in ampoule-syringe

    Active substance Dosage
    fulvestrant 250 mg

    ATC: L02BA03

    Manufacturer: EVER Pharma Jena GmbH

  • FULVESTRANT FRESENIUS KABI

    The medicine is used in postmenopausal women for the treatment of a certain type of breast cancer (locally advanced or metastatic) that is hormone receptor-positive. It may also be used in combination with palbociclib in women with hormone receptor-positive breast cancer (without HER2 overexpression).

    Form: solution for injection in ampoule-syringe

    Active substance Dosage
    fulvestrant 250 mg/5 ml

    ATC: L02BA03

    Manufacturer: Laboratorios Farmalán, S.A.

  • FULVESTRANT GLENMARK

    The medicine is used in women with a certain type of breast cancer that is estrogen receptor-positive or hormone receptor-positive, which is locally advanced or has metastasized. It may be used as a monotherapy or in combination with another medicine (palbociclib).

    Form: solution for injection in ampoule-syringe

    Active substance Dosage
    fulvestrant 250 mg/5 mL

    ATC: L02BA03

    Manufacturer: Laboratorios Farmalán, S.A.

  • FULVESTRANT MEDICAL VALLEY

    The medicine is used to treat postmenopausal women with a specific type of advanced or metastatic breast cancer that is hormone receptor-positive. It may also be used in combination with another medicine (palbociclib) in women with hormone receptor-positive breast cancer (without overexpression of the HER2 receptor).

    Form: solution for injection in ampoule-syringe

    Active substance Dosage
    fulvestrant 250 mg/5 ml

    ATC: L02BA03

    Manufacturer: Laboratorios Farmalán, S.A.

  • FULVESTRANT PHARMASCIENCE

    The medicine is used in postmenopausal women for the treatment of a specific type of breast cancer (locally advanced or metastatic). It may also be used in combination with another medicine (palbociclib) in women with a similar type of breast cancer who have not yet reached menopause.

    Form: solution for injection in ampoule-syringe

    Active substance Dosage
    fulvestrant 250 mg/5 ml

    ATC: L02BA03

    Manufacturer: Laboratorios Farmalán, S.A.

  • FULVESTRANT REDDY

    This medicine is used to treat postmenopausal women with a certain type of breast cancer (locally advanced or metastatic) that is hormone receptor-positive. It may also be used in combination with palbociclib in women with hormone receptor-positive breast cancer (without HER2 overexpression).

    Form: solution for injection in ampoule-syringe

    Active substance Dosage
    fulvestrant 250 mg

    ATC: L02BA03

    Manufacturer: Betapharm Arzneimittel GmbH

  • FULVESTRANT SANDOZ

    The medicine is used to treat postmenopausal women with a certain type of breast cancer (locally advanced or metastatic). It may also be used in combination with palbociclib in women with a certain type of breast cancer, whereby premenopausal women must also take a medicine called an LHRH agonist.

    Form: solution for injection in ampoule-syringe

    Active substance Dosage
    fulvestrant 250 mg/ 5ml

    ATC: L02BA03

    Manufacturer: Ebewe Pharma Ges.m.b.H Nfg. KG Fareva Unterach GmbH LEK Pharmaceuticals d.d.

  • FULVESTRANT STADA

    This medicine is used to treat postmenopausal women with a certain type of breast cancer (locally advanced or metastatic) that is hormone receptor-positive. It may also be used in combination with another medicine (palbociclib) in women with a similar type of breast cancer who do not have an overexpression of the HER2 receptor.

    Form: solution for injection in ampoule-syringe

    Active substance Dosage
    fulvestrant 250 mg/5 ml

    ATC: L02BA03

    Manufacturer: S.C. Rompharm Company S.R.L.

  • FULVESTRANT SUN

    The medicine is used to treat breast cancer in postmenopausal women (when the tumor is locally advanced or has metastasized) or in combination with another medicine (palbociclib) in the case of hormone receptor-positive breast cancer. In premenopausal women, it is used in combination with an additional medicine.

    Form: solution for injection in ampoule-syringe

    Active substance Dosage
    fulvestrant 250 mg/5 ml

    ATC: L02BA03

    Manufacturer: Sun Pharmaceutical Industries Europe B.V.

  • FULVESTRANT TEVA

    The medicinal product is used in postmenopausal women to treat a certain type of advanced or metastatic breast cancer with the presence of estrogen receptors. It may also be used in combination with another medicinal product (palbociclib) in women with hormone receptor-positive breast cancer.

    Form: solution for injection in ampoule-syringe

    Active substance Dosage
    fulvestrant 250 mg/ 5 ml

    ATC: L02BA03

    Manufacturer: PLIVA Hrvatska d.o.o. (Pliva Croatia Ltd.)

  • FULVESTRANT VIPHARM

    The medicine is used in postmenopausal women for the treatment of a certain type of breast cancer (estrogen receptor-positive) that is locally advanced or has metastasized. It may also be used in combination with another medicine (palbociclib) in women with hormone receptor-positive breast cancer.

    Form: solution for injection in ampoule-syringe

    Active substance Dosage
    fulvestrant 250 mg/5ml

    ATC: L02BA03

    Manufacturer: Laboratorios Farmalán, S.A.

  • FULVESTRANT ZENTIVA

    This medicine is used to treat postmenopausal women with a certain type of breast cancer (locally advanced or metastatic) that has estrogen receptors. It may also be used in combination with palbociclib in women with hormone receptor-positive breast cancer (without overexpression of the HER2 receptor).

    Form: solution for injection in ampoule-syringe

    Active substance Dosage
    fulvestrant 250 mg/5 ml

    ATC: L02BA03

    Manufacturer: Laboratorios Farmalán, S.A.

  • VASTALOMA

    The medicine is used to treat women with a certain type of breast cancer (with the presence of estrogen or hormonal receptors) that is locally advanced or has metastasized. It may be administered as monotherapy or in combination with palbociclib.

    Form: solution for injection

    Active substance Dosage
    fulvestrant No input provided

    ATC: L02BA03

    Manufacturer: Laboratorios Farmalán, S.A.